Deaths from<unk>  per million persons in 2012 Globally,<unk>  is common and increasing. Most recent epidemiological data suggests that<unk>  is in the top 10 for both prevalence and mortality (noted to be the 6th leading cause of<unk>  and 4th most common cause of death). The Global Burden of Disease<unk>  Collaboration found that from 1990 to 2015 the new cases of<unk>  per year increased by 75%. Estimates based on most recent data suggest that each year there are 841,000 new<unk>  diagnoses and 782,000 deaths across the globe.<unk>  is the most common<unk>  in Egypt, the Gambia, Guinea, Mongolia, Cambodia, and Vietnam. In terms of gender breakdown, globally<unk>  is more common in men than in women. Given that HCC is the most common type of<unk> , the areas around the world with the most new cases of HCC each year are Northern and Western Africa as well as Eastern and South-Eastern Asia. China has 50% of HCC cases globally, and more than 80% of total cases occur in sub-Saharan Africa or in East-Asia due to hepatitis B virus. In these high disease burden areas, evidence indicates the majority of the HBC and HCV infections occur via perinatal transmission (also called mother-to-child transmission). However, it is important to note that the risk factors for HCC varies by geographic region. For example, in China chronic HBV infection and aflatoxin are the largest risk factors; whereas, in Mongolia it is a combination of HBV and HCV co-infection and high levels of alcohol use that are driving the high levels of HCC. In terms of intrahepatic cholangiocarcinoma, we currently do not have sufficient epidemiological data because it is a rare<unk> . According to the United States National<unk>  Institute, the incidence of cholangiocarcinoma is not known. Cholangiocarcinoma also has a significant geographical distribution, with Thailand showing the highest rates worldwide due to the presence of liver fluke. In the United States there were 42,810 new cases of liver and intrahepatic bile duct<unk>  in 2020, which represents 2.4% of all new<unk>  cases in the United States. There are about 89.950 people who have liver and intrahepatic<unk>  in the United States. In terms of mortality, the 5-year survival rate for liver and intrahepatic bile duct<unk> s in the United States is 19.6%. In the United States there is an estimated 1% chance of getting<unk>  across the lifespan, which makes this<unk>  relatively rare. Despite the low number of cases, it is one of the top causes of<unk>  deaths.
Liver cancer
Liver tumor
Gallbladder cancer
Pancreatic cancer
Kidney cancer
Hepatitis
Cirrhosis
Liver abscess